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The putative presence of a mutation in codon 12 of the K-ras gene was investigated in the endometrium of tamoxifen (TAM) and
toremifene (TOR)-treated breast cancer patients. DNA was extracted from fresh cytologic samples of the endometrium in 86 TAM
and 21 TOR-treated breast cancer patients. Mutations were detected by enriched PCR and an enzyme-linked mini-sequence assay
(ELMA). K-ras mutation was found in 35 TAM-treated endometrial samples, and in only one TOR-treated endometrium (Po0.003).
In 24 premenopausal patients, K-ras mutation was found in seven (43.8%) of 16 patients with less than 47 months of TAM treatment,
while none was found in eight patients with more than 48 months of TAM treatment (Po0.03). In 62 postmenopausal-amenorrheic
patients, K-ras mutation was found in three (15.8%) of 19 patients with less than 23 months of TAM treatment, while it was found in
16 (61.5%) of 26 patients with 24–47 months of TAM treatment and nine (52.9%) of 17 patients with more than 48 months of TAM
treatment (P¼0.002). The presence of K-ras mutation is significantly influenced by the duration of TAM treatment and menstrual
status of the patients. TOR may have a lower potential genotoxicity than TAM.
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Tamoxifen (TAM) is a nonsteroidal triphenylethylene derivative
that has proven to be effective in the adjuvant treatment of breast
cancer by increasing both the disease-free period and overall
survival rate. Tamoxifen is generally well tolerated and had been
believed to have little side effects, but a number of large
epidemiological studies (Fisher et al, 1994; Rutqvist et al, 1995;
Bernstein et al, 1999; Bergman et al, 2000) have confirmed that the
relative risk of endometrial cancers is estimated to be two- to
three-fold of control, and the risk increases with both the duration
and cumulative dose of TAM treatment. Tamoxifen exhibits the
agonistic and antagonistic effects of oestrogen in different tissues,
depending on the ambient oestradiol concentration (Mourits et al,
2001). Several investigators have suggested the oestrogenic effect of
TAM on the development of endometrial cancer (Bernstein et al,
1999; Deligdisch et al, 2000).
On the other hand, TAM-DNA adducts are detected in a half of
the endometrial samples obtained from TAM-treated women
(Shibutani et al, 2000a). The site-specific dG-N
2-TAM adducts
display a high miscoding and mutagenic potential and primarily
generate G to T transversions in mammalian cells (Terashima et al,
1999). One study has concluded that if TAM-DNA adducts are not
repaired, then the potential risk of developing endometrial cancer
in the TAM-treated women may be increased (Shibutani et al,
2000b). Toremifene (TOR), a chlorinated TAM derivative, has been
also used for adjuvant hormonal treatment in breast cancer. Both
TAM and TOR have a similar oestrogenic activity in endometrial
cancer cells (O’Regan et al, 1998) and produce a similar increase in
the endometrial thickness of postmenopausal breast cancer
patients (Tomas et al, 1995). However, TOR has been reported
to show a lower genotoxicity than TAM (Shibutani et al, 2001).
In the ras gene superfamily, the codon 12 (-TGGTG-) of the
K-ras gene is the most frequently mutated codon in human
cancers. K-ras mutations are considered to correlate with the
phenotypic progression from atypical hyperplasia to endometrial
cancer. A mutation in codon 12 of the K-ras gene has been
identified in a range from 4.5 to 23% of atypical endometrial
hyperplasia cases (Lagarda et al, 2001; Sun et al, 2002) and in from
11 to 26% of endometrioid carcinomas of the endometrium
(Semczuk et al, 1998; Lax et al, 2000). The codons 12 and 14 of the
K-ras gene are reported to be hotspots for carcinogen-DNA adduct
formation in human bronchial epithelial cells (Feng et al, 2002).
The DNA adducts that formed at codon 12 of the K-ras gene were
poorly repaired in comparison to those at other codons, including
codon 14 (Feng et al, 2002). A high incidence of mutations in
codon 12 of the K-ras gene was also found in TAM-related
endometrial polyps (Hachisuga et al, 2003).
The purpose of the present study was to investigate any
differences in the frequency of mutations in codon 12 of the K-ras
gene in endometrial samples of patients treated with adjuvant
TAM or TOR. We also correlated the presence of K-ras mutations
with the duration of TAM treatment as well as ultrasonographically
confirmed increased thickness of the endometrium under different
conditions of menstruation.
MATERIALS AND METHODS
Patients
Since April 1993, gynaecologic examinations of patients who
received adjuvant hormonal treatment after undergoing surgery
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sfor breast cancers have been performed at the outpatient
gynaecologic clinic of the Fukuoka University Hospital. All
patients underwent a pelvic examination and Papanicolau cervical
smear tests followed by transvaginal ultrasonography (TVU), using
an Aloka 3500 sector scanner with a 5.0-MHz transvaginal
transducer (Aloka, Tokyo, Japan). The endometrial thickness was
recorded by measuring the double layer at the widest points
anteroposterior across the uterine cavity. An endometrial thick-
ness of less than 5mm is defined as normal in postmenopausal
women. Between February 2003 and September 2004, the
examinations for K-ras mutation in the endometrium were offered
117 breast cancer patients, who had received adjuvant hormonal
treatment. Four patients refused to undergo examination for K-ras
mutations. Although we tried to obtain endometrial cytologic
samples from all of the remaining 113 patients, it was not possible
in six patients due to cervical stenosis. As a result, 107 patients,
including 86 with TAM treatment and 21 patients with TOR
treatment, underwent examinations for the presence of K-ras
mutations. In total, 20 patients underwent anthracycline or taxane
based chemotherapy. In total, 15 patients underwent adjuvant
radiotherapy for the prevention of the local recurrence of breast
cancer. No patient underwent radiotherapy for castration of
ovarian function or received hormonal adjuvant therapy except
TAM, TAM and gonadotrophin-releasing hormone analogue
(GnRHa) or TOR. In addition, no patients demonstrated abnormal
cervical smear test findings in this study.
Specimen sampling
After a cervical smear test was performed, the discharge around
the uterine cervix was cleaned away to avoid any contamination
of the uterine cervical cells in the cytologic samples of the
endometrium. Fresh endometrial cytological samples were ob-
tained using an endocyte device (Laboratorie CCD, Paris, France).
The cellular material was divided into two parts: one was smeared
onto glass slides and processed for routine Papanicolaou staining
while the other was used for an analysis of a mutation in codon 12
of the K-ras gene. All endometrial smears in this study were
microscopically confirmed by cytopathologists to exhibit aggre-
gates of the endometrial glandular and stromal cells.
Detection of mutations in codon 12 of the K-ras gene
DNA was extracted from cytological specimens using the standard
phenol and chloroform method. Mutations in codon 12 of the
K-ras gene were analysed by an enriched polymerase chain
reaction (PCR)-enzyme-linked minisequence assay (ELMA)
(Sumitomo Metal Industry, Inc., Tokyo, Japan) (Matsubayashi
et al, 1999). This assay was based on the enrichment of the mutant
K-ras gene as previously described (Levi et al, 1991), followed by
incorporating a biotin-labelled nucleotide specific for the mutant
gene, which was then quantified enzymatically with a chromogenic
substance. The PCR amplified K-ras gene was captured by the
probes that were designed to detect the K-ras codon 12 wild type
(GGT) and six mutants (GAT, GCT, GTT, AGT, CGT, TGT), which
were ultimately measured using a microtitre plate reader for
detection and quantification. The results of semiquantitative
analysis were scored as (3þ), (2þ), (1þ), (þ ) and ( ),
according to the percentage of the mutant ras genes. Approxi-
mately (3þ), (2þ), (1þ), (þ ) and ( ) represented more than
20, 2–20, 0.2–2, less than 0.2% and none (not detected) of the
mutant, according to the manufacturer’s instructions. Quantitative
analysis of K-ras mutations is reported to provide a useful tool for
diagnosing pancreatic cancer when the percentage of K-ras
mutations is high (Tada et al, 2002a). We quantitatively divided
the presence of K-ras mutations into two groups: low (þ  and
þ) and high (2þ and 3þ).
The oligonucleotide primers were as follows: (1) upstream for
the first and second PCR, 50-TAAACTTGTGGTAGTTGGAACT-30;
(2) downstream for the first PCR, 50-GTTGGATCATATTCGTA
CAC-30 and (3) downstream for the second PCR, 50-CAAATG
ATCTGAATTAGCTG-30. In total, 1ml of a 10-fold dilution of the
first PCR product was digested with 2.5U of the restriction enzyme
BsrI (New England Biolabs, Beverly, MA, USA). The detailed
method has been described in previous studies (Matsubayashi et al,
1999; Hachisuga et al, 2003).
This study (no. 158) was approved by the ethics committee of
Fukuoka University School of Medicine. Informed content was
obtained from each patient.
Statistical analysis
The w
2 test was used to assess the association between categoric
variables. Statistical significance was considered to exist at a value
of Po0.05.
RESULTS
Analyses of patients undergoing TAM treatment
Clinical findings The age of the patients undergoing TAM
treatment ranged from 27 to 71 years with a mean of 50.5 years.
The patients were treated with 20mg of TAM daily for 3 to 121
months with a mean of 36.1 months (the TAM dose ranged from
1.8 to 72.6g). When examining for K-ras mutations, 24 patients
were found to have regular, irregular or oligomenorrheic
menstrual cycle and were classified as the premenopausal group.
Five TAM-related amenorrheic patients, five chemotherapy and
TAM-related amenorrheic patients and 15 Gn-RHa and TAM-
related amenorrheic patients were included into the amenorrheic
group. In total, 37 patients who had experienced menopause before
TAM treatment were classified as the postmenopausal group. The
endometrial thickness ultrasonographically ranged from 0.2 to
2.5cm with a mean of 0.8cm. In total, 25 (67.6%) of 37
postmenopsual patients showed an endometrial thickness of over
0.5cm, while only three (12.0%) of 25 amenorrheic patients
showed an endometrial thickness of over 0.5cm (Po0.001).
Histopathologic findings Histopathologic examination was per-
formed in 35 patients with vaginal bleeding and/or recommenda-
tion of the histopathologic examination from cytopathologists,
regardless of results of the K-ras mutation. The histopathologic
diagnoses were comprised of 10 atrophic endometrial samples, six
endometrial samples in the proliferative phase, three endometrial
samples in the secretory phase, 14 endometrial polyps and two
endometrial cancers. Of 51 TAM-treated patients without histo-
logic examination, 47 are being followed more than 1 year after
examination for K-ras mutation in our 6-month-interval gynaeco-
logic screening program. Endometrial cancer has not been found
in these patients.
K-ras mutations K-ras mutations were found in 35 (40.7%) of 86
patients undergoing TAM treatment (Table 1, Figure 1). Low levels
(þ or þ) and high levels (2þ or 3þ) of K-ras mutation were
found in 22 and 13 patients undergoing TAM treatment,
respectively. Two patients exhibited multiple K-ras mutations
(GTT of 2þ and GAT of 2þ, and GCT of 3þ and GAT of 3þ,
respectively). In total, 54 patients were examined for K-ras
mutation during TAM treatment and 32 patients after the cessation
of the TAM treatment. Seven (29.1%) of 24 premenopausal
patients, 18 (48.6%) of 37 postmenopasual patients and 10
(40.0%) of 25 amenorrheic patients were positive for K-ras
mutation. Table 2 shows the correlation between the duration of
TAM treatment and K-ras mutation in breast cancer patients
K-ras mutation and tamoxifen
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sduring and after cessation of TAM treatment. The positive rate of
K-ras mutation in the premenopausal group did not exhibit a
significant difference from that of the K-ras mutation in the
postmenopausal-amenorrheic group (P¼0.18). The positive rate
of K-ras mutation did not exhibit any significant difference
between patients during and after cessation of TAM treatment
both in the premenopausal (P¼0.13) and in postmenopausal-
amenorrheic (P¼0.39) groups. The high level of K-ras mutation
also did not reveal a significant difference between patients during
and after cessation of TAM treatment both in the premenopausal
(P¼0.25) and in postmenopausal-amenorrheic (P¼0.19) groups.
In the premenopausal group, K-ras mutation was seen in seven
(43.8%) of 16 patients with less than 47 months of TAM treatment,
while none was seen in eight patients with more than 48 months of
TAM treatment (Po0.03). In the postmenopausal-amenorrheic
group, K-ras mutation was found in three (15.8%) of 19 patients
with less than 23 months of TAM treatment, while it was found in
16 (61.5%) of 26 patients with 24–47 months of TAM treatment
and nine (52.9%) of 17 patients with more than 48 months of TAM
treatment (less than 23 months vs more than 24 months,
P¼0.002).
The positive rates of K-ras mutation were 45.0, 31.8 and 41.6%
in the TAM-treated patients with endometrial thicknesses of less
than 0.5, 0.6–0.9 and more than 1.0cm, respectively. There was no
significant correlation between the endometrial thickness and the
presence of K-ras mutation (Table 3). TAM-treated patients with
vaginal bleeding showed a greater frequency of endometrial
thickness of more than 1.0cm than those without vaginal bleeding
(Table 4, Po0.001). Among the patients with endometrial
thickness of greater than 1.0cm, the patients with vaginal bleeding
were more frequently detected to have a high level of K-ras
mutations than those without vaginal bleeding (Po0.02). The
correlation between K-ras mutation and certain histopathologic
features is shown in Table 5. The positive rate of K-ras mutation
was not siginificantly different between benign conditions,
including atrophy and endometrium in the proliferative and
sectretory phases, and neoplastic tumors including both polyps
and cancer (P¼0.40).
Seven (38.9%) of 18 patients with chemotherapy and 28
(41.2%) of 68 patients without chemotherapy were positive
for K-ras mutation (P¼0.86). No K-ras mutation was found in
the cytologic samples of the uterine cervix that were randomly
selected from 10 patients with the K-ras mutation positive
endometirum.
Table 1 Types of K-ras mutations in the 35 tamoxifen-treated patients
Type +  1+ 2+ 3+ Total
G A T 4362 1 5
G C T 3213 9
G T T 5321 1 1
A G T 0000 0
CGT 1 0 0 0 1
T G T 1000 1
Total 14 8 9 6 37
a
aTwo patients showed multiple K-ras mutations (GTT of 2+ and GAT of 2+, and
GCT of 3+ and GAT of 3+, respectively).
1234 5678
GAT
GCT
GGT
GT T
AGT
CGT
TGT
Back
Figure 1 Semiquantitative analysis of mutations in codon 12 of K-ras
using the enriched polymerase chain reaction (PCR)-enzyme-linked
minisequence assay (ELMA; Sumitomo Metal Industry, Tokyo, Japan).
Lanes 1and 2: toremifene-treated endometrium; lanes 3–8: tamoxifen-
treated endometrium. The mutation types as determined by PCR-ELMA
for lanes 1, 2, 5 and 8 were GGT (wild type), lane 3 was GAT(þ ), lane 4
was GAT (1þ), lane 6 was GAT (3þ) and lane 7 was GTT (1þ). BACK:
background.
Table 2 Duration of tamoxifen treatment and K-ras mutation in breast cancer patients during tamoxifen treatment and after cessation of tamoxifen
treatment
K-ras mutation during TAM
treatment
K-ras mutation after cessation
of TAM treatment
Duration
(months)
No. of
cases ( ) Low High
Positive
rate (%)
No. of
cases ( ) Low High
Positive
rate (%)
Premenopausal group
1–23 4 2 1 1 50.0 1 1 0 0 0.0
24–47 8 4 3 1 50.0 3 2 1 0 33.3
48 * 3 3 0 0 0.0 5 5 0 0 0.0
Postmenopausal-amenorrheic group
1–23** 14 12 2 0 12.5 5 4 0 1 20.0
24–47 13 6 6 1 53.8 13 4 5 4 69.2
48– 12 5 3 4 58.3 5 3 1 1 40.0
Total 54 30 15 7 32 19 7 6
*Po0.03 (less than 47 months vs more than 48 months). **P¼0.002 (less than 23 months vs more than 24 months).
K-ras mutation and tamoxifen
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sAnalyses of the patients undergoing TOR treatment
Clinical findings The age of the patients ranged from 41 to 86
years with a mean of 64.8 years. In total, 20 were postmenopausal
patients and one was a chemotherapy and TAM-related amenor-
rheic patient. A total of 18 patients were seen during and three
patients after cessation of TAM treatment. The patients were
treated with 40mg of TOR daily for 3–65 months with a mean of
29.4 months (the dose of TOR ranged from 3.6–78.0g). The
endometrial thickness ultrasonographically ranged from 0.3 to
2.2cm with a mean of 1.1cm. In total, 19 patients were found to
have an endometrial thickness of over 0.5cm.
Histopathologic findings Histopathologic examination was in
seven patients with vaginal bleeding and/or on the recommenda-
tion by cytopathologists of a histopathologic examination,
regardless of the results of the K-ras mutation status. The
histopathologic diagnoses were comprised of four endometrial
polyps, two atrophic endometrial samples and one endometrium
in the proliferative phase.
K-ras mutations In the 21 patients with TOR treatment, an 86-
year-old woman treated with 23 months of TOR treatment was
detected to have a low level (GAT; 1þ) of K-ras mutation. She
complained of vaginal bleeding and ultrasonograph revealed an
endometrial thickness of 1.2cm. Histologic diagnosis of the biopsy
specimen was an endometrial polyp.
DISCUSSION
New technological modalities such as the PCR have helped to
improve the molecular detection of cancer. One study reported
that K-ras mutations can be detected in DNA samples prepared
from endometrial aspirate specimens using the mutant-enriched
PCR technique (Al-Jehani et al, 1998). Nucleotide substitutions
identical to those found in the K-ras genes of the corresponding
tumor DNA samples were found in all endometrial aspirate DNA
samples in this study (Al-Jehani et al, 1998). Recently, a kit to
quantitatively detect K-ras mutations, combining enriched PCR
and ELMA, has been developed. The successful detection of K-ras
mutations from pancreatic juice of patients with pancreatic cancer
has been reported using this kit (Tada et al, 2002b).
One of the technical problems with cytologic sampling from
the uterine cavity using an endocyte device is the difficulty
of completely avoiding any contamination by the uterine
cervical cells. Therefore, a mutation in codon 12 of the K-ras gene
was randomly examined in cervical cell samples from 10 patients
with a K-ras mutation positive endometirum, and a mutation
in codon 12 of the K-ras gene was not detected in any cervical
cell samples.
The genes most commonly affected by sporadically acquired
point mutations in various types of cancers are in the ras gene
family. The patterns seen in point mutations in cancers are the
results of the interactions of three factors: (1) generation of an
altered DNA base or nucleotide; (2) faulty DNA repair and (3) the
biologic consequences of induced mutations (Kelly and Littman,
2002). In this study, the positive rates of K-ras mutation did not
exhibit any significant difference between the postmenopausal-
amenorrheic and the premenopausal groups. No K-ras mutation
was seen in premenopausal patients with more than 48 months of
TAM treatment, while it was seen in 52.9% of the postmenopausal-
amenorrheic patients with more than 48 months of TAM
treatment. Although the effect of the cessation of TAM treatment
Table 3 Endometrial thickness and K-ras mutation in tamoxifen-treated
breast cancer patients
K-ras mutation
Endometrial
thickness (cm)
No. of
cases ( ) Low High Positive rate (%)
Premenopausal group
 0.5 6 3 2 1 50.0
0.6 0.9 12 10 1 1 16.7
1.0  6 4 2 0 33.3
Amenorrheic group
 0.5 22 12 7 3 45.5
0.6–0.9 1 1 0 0 0.0
1.0  2200 0 . 0
Postmenopausal group
 0.5 12 7 3 2 41.7
0.6–0.9 9 4 3 2 55.6
1.0  16 8 4 4 50.0
Total 86 51 22 13 40.7
Table 4 Endometrial thickness and K-ras mutaion in tamoxifen-treated breast cancer patients with and without vaginal bleeding
Pateints with vaginal bleeding Patients without vaginal bleeding
K-ras mutation K-ras mutation
Endometrial
thickness (cm)
No. of
cases ( ) Low High Positive rate (%)
No. of
cases ( ) Low High Positive rate (%)
 0.5 2 1 0 1 50.0 32 15 12 5 53.1
0.6–0.9 1 1 0 0 0.0 27 20 4 3 25.9
1.0  11 4 3 4* 63.6 13 10 3 0 23.1
Total 14 6 3 5 57.1 72 45 19 8 37.5
*Po0.02 (patients with vaginal bleeding vs patients without vaginal bleeding).
Table 5 Histopathologic features and K-ras mutation in the 35
tamoxifen-treated patients
K-ras mutation
Endometrium No. of cases   Low High Positive rate (%)
Atrophy 10 4 4 2 60.0
Proliferative phase 6 2 4 0 66.7
Secretory phase 3 2 1 0 33.3
Polyp 14 8 1 5 42.9
Cancer 2 1 1 0 50.0
Total 35 17 11 7 51.4
K-ras mutation and tamoxifen
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son the presence of the K-ras mutation needs to be better evaluated
in a large case study, these results do suggest that menstruation
probably plays an important role in the removal of K-ras
mutations from the endometrium.
An increased risk of endometrial cancer has been specifically
described in postmenopausal women, and this risk increases as the
duration of TAM treatment increases (Fisher et al, 1994; Rutqvist
et al, 1995; Bergman et al, 2000). Recently, in a chemoprevention
trial, endometrial cancers were reported in patients who were
premenopausal at the start of TAM treatment and who became
amenorrheic during long-term TAM treatment along with having
low serum oestrogen levels (Chang et al, 1998). The duration-
related distribution of the K-ras mutation in amenorrheic patients
was almost the same as that of the K-ras mutation in
postmenopausal patients. Postmenopausal-amenorrheic patients
with less than 23 months of TAM treatment exhibited a
significantly lower incidence of K-ras mutations than did those
with more than 24 months of TAM treatment.
In a quantitative analysis of K-ras mutations, the high level of
the K-ras mutation was not positively associated with neoplastic
changes, but it is interesting that a high level of K-ras mutation was
more frequently found in symptomatic patients with endometrial
thickness of greater than 1.0cm. A large case study will need to be
undertaken to clarify this provocative finding.
One previous study showed that endometrial thickness sig-
nificantly increased during the course of treatment with no
differences between TAM and TOR (Tomas et al, 1995). The
authors of this study suggest TOR to have an oestrogenic effect on
the endometrium similar to that of TAM. This finding has been
confirmed in this report. Of the 21 TOR-treated patients, 19 had an
endometrial thickness of over 0.5cm, but only one K-ras mutation
was detected in these patients. There is no correlation between
endometrial thickness and K-ras mutation in the TAM-treated
patients.
In summary, K-ras mutation was found in 40.7% of TAM-
treated endometrium samples, whereas K-ras mutation was found
in one TOR-treated endometrium. TOR may have a lower potential
genotoxicity than TAM. Although the effect of the cessation of
TAM treatment on the presence of the K-ras mutation needs to be
more thoroughly evaluated in a large case study, these results
appear to suggest that menstruation plays an important role in the
removal of K-ras mutations. The presence of the K-ras mutation is
significantly influenced by the duration of TAM treatment, but it
does not correlate with endometrial thickness as measured by
ultrasonography.
ACKNOWLEDGEMENTS
This study was supported by a Grant-in-Aid for Scientific Research
C (No. 14571597) from the Ministry of education, Science and
Culture, Japan (TH). We appreciate the review of the manuscript
prior to final submission by Pacific Edit.
REFERENCES
Al-Jehani RM, Jeyarajah AR, Hagen B, Hogdall EV, Oram DH, Jacobs IJ
(1998) Model for the molecular genetic diagnosis of endometrial cancer
using K-ras mutation analysis. J Natl Cancer Inst 90: 540–542
Bergman L, Beelen MLR, Gallee MPW, Hollema H, Benraadt J, Leeuwen FE,
the Comprehensive Cancer Centres’ALERT Group (2000) Risk and
prognosis of endometrial cancer after tamoxifen for breast cancer.
Lancet 36: 881–887
Bernstein L, Deapen D, Cerhan JR, Schwartz SM, Liff J, Maloney EM,
Perlman JA, Ford L (1999) Tamoxifen therapy for breast cancer and
endometrial cancer risk. J Natl Cancer Inst 91: 1654–1662
Chang J, Powles TJ, Ashley SE, Gregory IRK, Dowsett M (1998) Variation in
endometrial thickening in women amenorrhea on tamoxifen. Breast
Cancer Res Treat 48: 81–85
Deligdisch L, Kalir T, Cohen CJ, Latour MD, Bouedec GL, Llorca FP (2000)
Endometrial histopathology in 700 patients treated with tamoxifen for
breast cancer. Gynecol Oncol 78: 181–196
Feng Z, Hu W, Chen JX, Pao A, Li H, Rom W, Hung MC, Tang MS (2002)
Preferantial DNA damage and poor repair determine ras gene mutational
hotspot in human cancer. J Natl Cancer Inst 94: 1527–1536
Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin
WM (1994) Endometrial cancer in tamoxifen-treated breast cancer
patients: findings from the National Surgical Adjuvant Breast and Bowel
Projects (NSABP)B-14. J Natl Cancer Inst 86: 527–537
Hachisuga T, Miyakawa T, Tsujioka H, Horiuchi S, Emoto M, Kwarabayashi
T (2003) K-ras mutation in tamoxifen-related endometrial polyps.
Cancer 98: 1890–1897
Kelly MJ, Littman SJ (2002) Etiology of the mutational spectrum of ras
genes in human carcinomas. J Natl Cancer Inst 94: 1516–1517
Lagarda H, Catasus L, Arguelles R, Guiu XM, Prat J (2001) K-ras mutations
in endometrial carcinomas with microsatellite instability. J Pathol 193:
193–199
Lax SF, Kendall B, Tashiro H, Siebos RJC, Ellenson LH (2000) The
frequency of p53, K-ras mutations, and microsatellite instability differs
in uterine endometrioid and serous carcinoma. Evidence of distinct
molecular genetic pathways. Cancer 88: 814–824
Levi S, Urbano-Ispizua A, Gill R, Thomas DM, Gilbertson J, Foster C,
Marshall CJ (1991) Multiple K-ras codon 12 mutations in cholangio-
carcinomas demonstrated with a sensitive polymerase chain reaction
technique. Cancer Res 51: 3497–3502
Matsubayashi H, Watanabe H, Yamaguchi T, Ajioka Y, Nishikura K,
Iwafuchi M, Yamano M, Kijima H, Saito T (1999) Multiple K-ras
mutations in hyperplasia and carcinoma in cases of human pancreatic
carcinoma. Jpn J Cancer Res 90: 841–848
Mourits MJE, Vries EGED, Willemse PHB, Hoor KAT, Hollema H, Zee
AGJVD (2001) Tamoxifen treatment and gynecologic side effects: a
review. Obstet Gynecol 97: 855–866
O’Regan RM, Cisneros A, England GM, MacGregor JI, Muenzner HD,
Assikis VJ, Bilimoria MM, Piette M, Dragan YP, Pitot HC, Chatterton R,
Jordan VC (1998) Effects of the antiestrogens tamoxifen, toremifene
and ICI182780 on endometrial cancer growth. J Natl Cancer Inst 90:
1552–1558
Rutqvist LE, Johansson H, Signomklao T, Johansson U, Fornander T,
Wilking N (1995) Adjuvant tamoxifen therapy for early stage breast
cancer and second primary malignacies. J Natl Cancer Inst 87: 645–651
Semczuk A, Berbec H, Kostuch M, Cybulski M, Wojcierowski J, Baranowski
W (1998) K-ras gene point mutations in human endometrial carcinomas:
correlation with clinocopathological features and patient’s outcome.
J Cancer Res Clin Oncol 124: 695–700
Shibutani S, Ravindernath A, Suzuki N, Terashima I, Sugarman SM,
Grollman AP, Pearl M (2000a) Identification of tamoxifen-DNA adducts
in the endometrium of women treated with tamoxifen. Carcinogenesis 21:
1461–1467
Shibutani S, Ravindernath A, Terashima I, Suzuki N, Laxmi YRS, Kanno Y,
Suzuki M, Apak TI, Sheng JJ, Duffel MW (2001) Mechanism of lower
genotoxicity of toremifene compared with tamoxifen. Cancer Res 61:
3925–3931
Shibutani S, Reardon JT, Suzuki N, Sancar A (2000b) Excision of
tamoxifen-DNA adducts by the human nucleotide excicion repair
system. Caner Res 60: 2607–2610
Sun H, Enomoto T, Shroyer KR, Ozaki K, Fujita M, Ueda Y, Nakashima R,
Kuragaki C, Ueda G, Murata Y (2002) Clonal analysis and mutations in
the PTEN and the K-ras genes in endometrial hyperplasia. Diagn Mol
Pathol 11: 204–211
Tada M, Komatsu Y, Kawabe T, Sasahira N, Isayama H, Toda N, Shiratori
Y, Omata M (2002a) Quantitative analysis of K-ras gene mutation in
pancreatic tissue obtained by endoscopic ultrasonography-guided fine
needle aspiration: Clinical utility for diagnosis of pancreatic tumor. Am J
Gastroenterol 97: 2263–2270
K-ras mutation and tamoxifen
T Hachisuga et al
1102
British Journal of Cancer (2005) 92(6), 1098–1103 & 2005 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sTada M, Tateishi K, Kawabe T, Sasahira N, Isayama H, Komatsu Y,
Shiratori Y, Omata M (2002b) Quantity of mutant K-ras gene in
pancreatic secretions for diagnosis of pancreatic carcinoma with
different assays: analysis of 100 patients. Clin Chim Acta 324: 105–111
Terashima I, Suzuki N, Shibutani S (1999) Mutagenic potential of alpha-
(N
2-Deoxyguaanosinyl) tamoxifen lesions, the major DNA adducts
detected in endometrial tissues of patients treated with tamoxifen.
Cancer Res 59: 2091–2095
Tomas E, Kaupplia A, Blanco G, Apaja-Sarkkinen M, Laatikainen T (1995)
Comparison between the effects of tamoxifen and toremifene on
the uterus in postmenopausal breast cancer patients. Gynecol Oncol 59:
261–266
K-ras mutation and tamoxifen
T Hachisuga et al
1103
British Journal of Cancer (2005) 92(6), 1098–1103 & 2005 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
s